Allarity Begins Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

• Allarity begins Phase 2 trial of stenoparib in advanced ovarian cancer
• Stenoparib targets both PARP and WNT pathways for dual-action therapy
• Trial includes DRP companion diagnostic to identify responsive patients

Allarity Therapeutics, a Phase 2-stage biopharmaceutical with activities in Copenhagen and Boston, has formally enrolled its first patient in its newly launched Phase 2 trial of stenoparib—a dual PARP and WNT pathway inhibitor—against advanced, platinum-resistant or platinum-ineligible ovarian cancer.

Its revised trial protocol is intended to propel the drug development of stenoparib in combination with its Drug Response Predictor (DRP) companion diagnostic (CDx) to maximize the pathway to eventual FDA approval.

Thomas Jensen, CEO of Allarity Therapeutics said “With this enrollment, we’re taking a critical step toward offering a safer, more targeted alternative to chemotherapy for women battling recurrent ovarian cancer, and the trial reflects valuable input from top gynecologic oncologists and reinforces the potential of our DRP to identify patients most likely to benefit from stenoparib.”

Also Read: Alembic Pharma Achieves Major Milestone with USFDA Nod for Cancer Treatment

The research will also assess the effect of stenoparib on the WNT pathway—a leading force in cancer growth—and how it compares to first-generation PARP inhibitors on a clinical basis in terms of enhanced safety and therapeutic accuracy.

There will be significant trial data in late summer 2026, and Allarity intends to file for several accelerated regulatory pathways for the approval of stenoparib and the DRP CDx.